Abstract: There is an urgent need to identify new drug targets for Alzheimer’s disease (AD). While new immunotherapies show promise, clinical benefit appears low, and side effects are high. A greater understanding of the disease mechanisms driving AD is an essential factor that will facilitate the identification of new, effective drug targets. Historically, the pathological roles of amyloid-beta and phosphorylated tau have been the primary research focus of the AD field. However, the influx of data from omics studies over the last decade has convincingly demonstrated that there are thousands of molecular changes that occur in human brain tissue throughout AD, including many that could be disease drivers, novel drug targets, and biomarkers. Excellent progress has particularly been made in the AD proteomics field (Bai et al., 2021; Rayaprolu et al., 2021). The goal of our recent study (Askenazi et al., 2023) was to amalgamate this wealth of new proteomic data into a new open-access and user-friendly resource – NeuroPro (https://neuropro.biomedical.hosting/; Askenazi et al., 2023) – which provides a comprehensive roadmap of all protein changes present in human AD brain tissue. NeuroPro currently combines data from 38 proteomic studies of human AD brain tissue that were carefully curated and harmonized. Currently, NeuroPro provides information about protein changes across thirteen brain regions, three disease stages (preclinical AD, mild cognitive impairment, and advanced AD), and three neuropathological features present in AD (amyloid plaques, neurofibrillary tangles, and cerebral amyloid angiopathy). Our goal is to continue to update NeuroPro as additional proteomic studies are published in the future.